2B70:F:F-iShares NASDAQ US Biotechnology UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 5.914

Change

+0.06 (+1.04)%

Market Cap

USD 0.49B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

+0.29 (+1.13%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.70 (+1.41%)

USD 115.04B
FRCJ:F UBS MSCI Japan Socially Respon..

+0.15 (+0.69%)

USD 83.57B
SXR8:F iShares Core S&P 500 UCITS ETF..

+7.24 (+1.46%)

USD 80.45B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+0.58 (+1.10%)

USD 76.57B
EUNL:F iShares Core MSCI World UCITS ..

+1.07 (+1.20%)

USD 72.04B
SXRZ:F iShares VII PLC - iShares Nikk..

+2.55 (+1.14%)

USD 58.19B
XDNY:F Xtrackers MSCI Japan ESG Scree..

+0.17 (+1.17%)

USD 56.18B
VUSA:F Vanguard Funds Public Limited ..

+1.71 (+1.93%)

USD 51.63B
VUAA:F Vanguard S&P 500 UCITS Acc

+1.68 (+1.90%)

USD 49.95B

ETFs Containing 2B70:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.79% 53% F 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.79% 51% F 56% F
Trailing 12 Months  
Capital Gain 10.32% 57% F 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.32% 55% F 58% F
Trailing 5 Years  
Capital Gain 32.82% 56% F 62% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 32.82% 56% F 49% F
Average Annual (5 Year Horizon)  
Capital Gain 6.84% 76% C+ 73% C
Dividend Return 6.84% 76% C+ 67% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 14.90% 37% F 66% D+
Risk Adjusted Return 45.94% 80% B- 82% B
Market Capitalization 0.49B 62% D 50% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.